This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Non-alcoholic fatty liver disease (NAFLD) is a condition caused by the buildup of excess fat in the liver. It is a common condition and affects up to one in five people in the United States. NAFLD is associated with obesity, diabetes, and other metabolic disorders. It is typically asymptomatic and can lead to more serious conditions, such as cirrhosis and liver cancer. NAFLD is often seen in people with metabolic syndrome, which includes conditions such as obesity, high blood pressure, high triglycerides, and low levels of "good" cholesterol. These conditions are associated with insulin resistance, which can lead to NAFLD. Other risk factors for NAFLD include a high-fat diet, sedentary lifestyle, and certain medications, such as those used to treat high cholesterol or diabetes. NAFLD can also be seen in people who are not obese or have metabolic syndrome. Other diseases that may be associated with NAFLD include autoimmune conditions such as lupus, rheumatoid arthritis, and celiac disease; certain genetic diseases such as hemochromatosis and Wilson's disease; and certain viral infections such as Hepatitis C. The main treatment for NAFLD is lifestyle modification. This includes eating a healthy diet, exercising regularly, and maintaining a healthy weight. If necessary, medications such as statins may be used to reduce cholesterol and other fats in the blood. In some cases, liver transplantation may be necessary. It is important to consult with your doctor if you have any of the conditions associated with NAFLD. Early diagnosis and treatment can help prevent more serious complications, such as cirrhosis and liver cancer.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States